RxDoctor Payments Data

Joseph Johnson, MD

Gastroenterology · San Antonio, TXNPI 1477557072

Payments from drug & device makers

$835in general payments, 2019–2025

Across 41 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$328
  • AbbVie$223
  • Echosens North America, Inc.$108
  • Merck$59
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$56
  • Shionogi Inc$31
  • plus $31 from 3 others

What the payments were for

  • Food & beverage$73788%
  • Education$9812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$835 in reported general payments places this provider in the 20th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$121,254
Medicare patients
588
Services billed
961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab11$72,150
ClenpiqSod Picosulf/Mag Ox/Citric Ac307$51,985
LinzessLinaclotide41$37,828
XifaxanRifaximin13$32,393
Dexlansoprazole DrDexlansoprazole84$21,610
Mesalamine28$8,799
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates80$4,822
Pantoprazole Sodium411$3,723
Omeprazole296$3,400
Famotidine231$3,140
Sucralfate79$2,815
Esomeprazole Magnesium69$1,857
SutabSod Sulf/Pot Chloride/Mag Sulf11$1,780
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl72$968
Ursodiol12$850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$223$37,82841 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$56$32,39313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →